EMA Revoked: Dimethyl fumarate Neuraxpharm (dimethyl fumarate) — Laboratorios Lesvi S.L.

View source ↗

Summary

The EMA has revoked the Dimethyl fumarate product from Laboratorios Lesvi S.L. for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Dimethyl fumarate (Dimethyl fumarate)

Snippet

Status: Revoked. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Laboratorios Lesvi S.L.. Decision date: 13/12/2023